Breast cancers “Our patients receive support at every level, including psychological support” Dr Martine Piccart, Medical Oncologist and Scientific Director How we treat breast cancers In Belgium, one woman in eight will develop breast cancer over the course of her life. The Institut Jules Bordet treats around 700 women a year. Our multidisciplinary teams were pioneers in a number of diagnostic and therapeutic approaches to these cancers. ...
Rare tumours “The Institut Jules Bordet has long been recognised for its treatment of rare tumours” Dr Ahmad Awada, Oncologist How we treat rare tumours Rare tumours account for around a quarter of the cancers treated at the Institut Jules Bordet. These cancers require very particular and multidisciplinary treatment. A tumour is described as rare when it affects fewer than 6 people in 100,000. It may appear in an organ or in tissue that is only very rarely affected by cancer (eg: the salivary glands, the penis, etc), or may be situated in an organ where cancer is relatively common but show cell characteristics that are different from those usually observed. ...
Gynaecological cancers How we treat gynaecological cancers The term gynaecological cancer covers cancers of the endometrium, the ovaries, the cervix, the vulva and the vagina. These intimate cancers require multidisciplinary, personalised care and treatment. Diagnosis – examinations required ...
Lung and thorax cancers “The therapeutic strategy depends on the type of cancer, its extent and the patient’s general state of health.” Dr Thierry Berghmans, Head of the Thoracic Oncology Clinic How we treat cancers of the lungs and thoracic cavity Thanks to extensive internal and external collaboration, the Institut Bordet is able to treat all cancers of the thoracic cavity, including lung cancer.Several types of cancer can develop in the thorax: small and large cell lung (or “bronchial”) cancer, pulmonary metastases originating in other primary tumours and rare tumours such as cancer of the thymus, mesothelioma, pleura, etc. ...
Blood cell cancers « Advances in research and treatment while supporting and listening to the patient: the keys to recovery and quality of life » Prof Nathalie Meuleman, HEAD OF THE DEPARTMENT OF HAEMATOLOGY-ONCOLOGY at the Institut Jules Bordet. How we treat blood cell cancers The Institut Jules Bordet treats all haematological cancers, ie blood cell and lymphatic cancers. ...
Prostate cancers “Our aim is to preserve the patient’s quality of life while treating the tumour as effectively as possible.” Dr Alexandre Peltier, Urological surgeon How we treat the prostate cancers Prostate cancer is the most common cancer in men. The Institut Jules Bordet has the cutting-edge technology needed to detect and treat these tumours. ...
Head and neck cancers « Providing comprehensive care for the patient is important for our multidisciplinary team but equally important is providing it without delay ... » Delphine Talmon, Oncological Care Coordinating Nurse (ICSO) How we treat ENT cancers of the head and neck Head and neck cancers include all tumours that develop in the upper aerodigestive tract and ENT (ear, nose and throat) system: tongue, cheek, palate, nose, sinuses, salivary glands, larynx, pharynx, etc. ...
Skin cancers “The quality of life of our patients is at the centre of our multidisciplinary care” Prof. Annie Drowart, Coordinator of the “skin” COM of the Institut Jules Bordet. How we treat skin cancers The Institut Jules Bordet treats all skin cancers: melanomas, spinocellular carcinomas, basocellular carcinomas, Merkel cell carcinomas, etc. ...
Thyroid cancers “The therapeutic strategy depends largely on the risk of persistence or recurrence of the disease.” Dr Giuseppe Costante, Endocrinologist and Head of Thyroid Cancer at the EURACAN Project. How we treat thyroid cancers The Institut Jules Bordet treats all types of thyroid cancer. The great majority can be cured but require correct assessment of the risk of recurrence and follow-up care for life. ...
Colorectal cancers “Our philosophy is to care for patients while sparing them any pointless and difficult treatments.” Dr Alain Hendlisz, Coordinator of the Digestive Tumour CMO, Institut Bordet How we treat cancers of the colon or rectum Colorectal cancers are among the most common forms of cancer. Significant advances have been made in improving the way they are treated. Treatment requires a multidisciplinary approach. ...
Digestive cancers “Combining several treatments increases the chance of a cure and reduces recurrence of digestive cancer.” Dr Alain Hendlisz, Coordinator of the Digestive CMO, Institut Jules Bordet. How we treat digestive tract cancers All the digestive organs can be affected by cancer: the oesophagus, stomach, pancreas, gall bladder and bile ducts, the small intestine, large intestine (colon) … even the anal margin. Management of these tumours is always multidisciplinary. ...
Information notice concerning the protection of your personal data Protection of privacy The Jules Bordet Institute (hereinafter "The Institution") is committed to providing you, as a patient and independently of your income, your insurability status, your origins or your philosophical beliefs, with the best possible welcome, optimal medical and paramedical care and appropriate socia...
Practical informations Your visit to the Institut Jules Bordet Documents to take with you Identity ...
Urological and male genital cancers “Our patients are supported by a team of medical and paramedical specialists.” Dr Alexandre Peltier, UROLOGICAL SURGEON How we treat male urological and genital cancers Urogenital cancers are tumours that develop in the urinary or genital system. ...
Neuroendocrine tumours “A neuroendocrine tumour is a particular kind of digestive cancer that requires very specific management.” Dr Alain Hendlisz, Coordinator of the Digestive Tumour CMO, Institut Bordet. How we treat neuroendocrine tumours Although often situated in an organ of the digestive tract, neuroendocrine tumours behave differently from other digestive cancers and must often be treated in a specific way. ...
Bone and soft tissue cancers How we treat bone and soft tissue cancers The medical team at the Institut Jules Bordet treats tumours that appear in the soft tissue (muscles, fat, nerves, blood vessels, etc), primary bone cancer in children (in close collaboration with HUDERF – the Hôpital Universitaire des Enfants Reine Fabiola) and in adults as well as bone metastases. ...
Liver cancers “A surgeon never takes the decision to operate on their own. The management of hepatic tumours is always multidisciplinary.” Dr Vincent Donckier, Hepatobiliary surgeon and head of surgery, Institut Bordet. How we treat liver cancers There are 2 types of hepatic cancer: primary liver cancer and hepatic metastases originating from other primary tumours. Surgery is the major treatment for these cancers but it is limited by the need to conserve sufficient functional liver tissue. Other therapies may be combined with surgery. ...
Brain tumours « Neuro-Oncology is above all a multidisciplinary approach at the centre of which the quality of life of the patient is crucial » Dr Philippe Martinive Clinic Director How we treat brain tumours The Institut Jules Bordet treats both primary brain cancers and brain metastases. Medical imaging plays a major role in this treatment because, in the brain, accurate definition of the tumour is crucial. ...
Confidentiality policy What is a cookie? A cookie is a small data file that can be placed on your computer when you visit websites. Cookies can be placed and/or read when you consult a website or mobile application for example or when you install or use a software programme, irrespective of the terminal you are using: computer, smartphone, digital tablet or video game console connected to the...
Radiotherapy Our role Radiotherapy is one of the main treatments for cancer and is used as an independent treatment or in combination with surgery and/or systemic treatment (i.e. chemotherapy). The goal is to cure cancer, to augment the prognosis, or to palliate symptoms.Radiation therapy has a biological effect on the DNA and the inflammatory status of the tumor. The side effects are decrease...